Hans Ehrsson

4.5k total citations
121 papers, 3.6k citations indexed

About

Hans Ehrsson is a scholar working on Oncology, Spectroscopy and Molecular Biology. According to data from OpenAlex, Hans Ehrsson has authored 121 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 26 papers in Spectroscopy and 25 papers in Molecular Biology. Recurrent topics in Hans Ehrsson's work include Analytical Chemistry and Chromatography (25 papers), Cancer Treatment and Pharmacology (21 papers) and Chemotherapy-induced organ toxicity mitigation (10 papers). Hans Ehrsson is often cited by papers focused on Analytical Chemistry and Chromatography (25 papers), Cancer Treatment and Pharmacology (21 papers) and Chemotherapy-induced organ toxicity mitigation (10 papers). Hans Ehrsson collaborates with scholars based in Sweden, United States and Norway. Hans Ehrsson's co-authors include Staffan Eksborg, Inger Wallin, Moustapha Hassan, Elin Jerremalm, Anita Andersson, Göran Laurell, Rolf Lewensohn, Elias S.J. Arnér, Jeffrey Yachnin and Olle Gyllenhaal and has published in prestigious journals such as Analytical Chemistry, JNCI Journal of the National Cancer Institute and Free Radical Biology and Medicine.

In The Last Decade

Hans Ehrsson

120 papers receiving 3.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Hans Ehrsson 1.2k 1.1k 573 411 313 121 3.6k
Giuliano Ciarimboli 1.6k 1.4× 834 0.8× 152 0.3× 146 0.4× 95 0.3× 95 3.3k
Rita Gatti 271 0.2× 1.0k 0.9× 97 0.2× 456 1.1× 144 0.5× 142 3.3k
David Schachter 549 0.5× 1.9k 1.8× 281 0.5× 167 0.4× 139 0.4× 102 5.1k
Richard F. Borch 1.1k 0.9× 2.4k 2.2× 167 0.3× 414 1.0× 2.2k 7.1× 93 5.4k
J. Lankelma 3.4k 2.8× 2.0k 1.8× 197 0.3× 186 0.5× 130 0.4× 77 5.0k
Mark J. McKeage 3.3k 2.7× 1.7k 1.5× 245 0.4× 76 0.2× 1.2k 3.9× 143 5.5k
Ursula Rauen 191 0.2× 1.3k 1.2× 477 0.8× 184 0.4× 101 0.3× 145 5.4k
Renty Franklin 1.5k 1.2× 2.3k 2.1× 450 0.8× 541 1.3× 141 0.5× 109 6.8k
Eva Frei 1.3k 1.1× 2.7k 2.5× 66 0.1× 126 0.3× 439 1.4× 231 5.8k
Leo W. J. Klomp 3.1k 2.5× 3.2k 2.9× 837 1.5× 305 0.7× 128 0.4× 90 8.9k

Countries citing papers authored by Hans Ehrsson

Since Specialization
Citations

This map shows the geographic impact of Hans Ehrsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Ehrsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Ehrsson more than expected).

Fields of papers citing papers by Hans Ehrsson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Ehrsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Ehrsson. The network helps show where Hans Ehrsson may publish in the future.

Co-authorship network of co-authors of Hans Ehrsson

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Ehrsson. A scholar is included among the top collaborators of Hans Ehrsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Ehrsson. Hans Ehrsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wallin, Inger, Göran Laurell, Maria C. Shoshan, et al.. (2014). Cisplatin and oxaliplatin are toxic to cochlear outer hair cells and both target thioredoxin reductase in organ of Corti cultures. Acta Oto-Laryngologica. 134(5). 448–454. 30 indexed citations
2.
Wallin, Inger, et al.. (2013). Cochlear pharmacokinetics of cisplatin: An in vivo study in the guinea pig. The Laryngoscope. 123(12). 3172–3177. 31 indexed citations
3.
Jerremalm, Elin, et al.. (2009). Oxaliplatin neurotoxicity – no general ion channel surface-charge effect. Journal of Negative Results in BioMedicine. 8(1). 2–2. 14 indexed citations
4.
Pierre, Pernilla Videhult, et al.. (2008). High concentrations of thiosulfate in scala tympani perilymph after systemic administration in the guinea pig. Acta Oto-Laryngologica. 129(2). 132–137. 8 indexed citations
5.
Jerremalm, Elin, Inger Wallin, Jeffrey Yachnin, & Hans Ehrsson. (2006). Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. European Journal of Pharmaceutical Sciences. 28(4). 278–283. 28 indexed citations
7.
Hansson, Johan, Hans Ehrsson, Staffan Eksborg, et al.. (2004). High‐Dose Cisplatin With Amifostine: Ototoxicity and Pharmacokinetics. The Laryngoscope. 114(9). 1660–1667. 29 indexed citations
8.
Bender, Johanna, et al.. (2004). Transdermal delivery from a lipid sponge phase—iontophoretic and passive transport in vitro of 5-aminolevulinic acid and its methyl ester. Journal of Controlled Release. 100(2). 191–198. 53 indexed citations
9.
Gullbo, Joachim, Elin Lindhagen, Hans Ehrsson, et al.. (2004). Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo. Investigational New Drugs. 22(4). 411–420. 21 indexed citations
10.
Gullbo, Joachim, Malin Wickström, Hans Ehrsson, et al.. (2003). Activity of Hydrolytic Enzymes in Tumour Cells is a Determinant for Anti-tumour Efficacy of the Melphalan Containing ProdrugJ1. Journal of drug targeting. 11(6). 355–363. 41 indexed citations
11.
Lindblad, K, M L Savontaus, Giovanni Stévanin, et al.. (1996). An expanded CAG repeat sequence in spinocerebellar ataxia type 7.. Genome Research. 6(10). 965–971. 85 indexed citations
12.
Andersson, Anita, Jan Fagerberg, Rolf Lewensohn, & Hans Ehrsson. (1996). Pharmacokinetics of Cisplatin and Its Monohydrated Complex in Humans. Journal of Pharmaceutical Sciences. 85(8). 824–827. 70 indexed citations
13.
Laurell, Göran, et al.. (1995). Distribution of cisplatin in perilymph and cerebrospinal fluid after intravenous administration in the guinea pig. Cancer Chemotherapy and Pharmacology. 36(1). 83–86. 33 indexed citations
14.
Andersson, Anita & Hans Ehrsson. (1994). Determination of cisplatin and cis-diammineaquachloroplatinum(II) ion by liquid chromatography using post-column derivatization with diethyldithiocarbamate. Journal of Chromatography B Biomedical Sciences and Applications. 652(2). 203–210. 49 indexed citations
15.
Ehrsson, Hans, et al.. (1993). Pharmacokinetics of peptichemio in myeloma patients: release ofm-l-sarcolysin in vivo and in vitro. Cancer Chemotherapy and Pharmacology. 31(4). 265–268. 9 indexed citations
16.
Hassan, Moustapha, Göran Berg, Hans Ehrsson, et al.. (1989). Pharmacokinetic and metabolic studies of high-dose busulphan in adults. European Journal of Clinical Pharmacology. 36(5). 525–530. 119 indexed citations
17.
Hassan, Moustapha, Hans Ehrsson, Inger Wallin, & Staffan Eksborg. (1988). Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain. European Journal of Drug Metabolism and Pharmacokinetics. 13(4). 301–305. 30 indexed citations
18.
Hassan, Moustapha & Hans Ehrsson. (1987). Urinary metabolites of busulfan in the rat.. Drug Metabolism and Disposition. 15(3). 399–402. 40 indexed citations
19.
Beran, Miloslav, Börje S. Andersson, Staffan Eksborg, & Hans Ehrsson. (1979). Comparative studies on the in vitro killing of human normal and leukemic clonogenic cells (CFUc) by daunorubicin, daunorubicinol, and daunorubicin-DNA complex. Cancer Chemotherapy and Pharmacology. 2(1). 19–24. 23 indexed citations
20.
Ehrsson, Hans, et al.. (1971). Quantitative gas chromatographic determination of picogram quantities of phenols.. PubMed. 8(3). 319–28. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026